Bridging the Translational Gap in Heart Failure Research: Using Human iPSC-derived Cardiomyocytes to Accelerate Therapeutic Insights

Area of Science:

• Cardiovascular Research
• Regenerative Medicine
• Stem Cell Biology

Background:

• Heart failure (HF) is a major global health concern with increasing prevalence and mortality.
• Traditional animal models for HF research have limitations in accurately reflecting human disease mechanisms and translating findings to clinical practice.
• A significant translational gap exists in understanding and treating human HF effectively.

Purpose of the Study:

• To review the advantages and limitations of conventional and innovative methods for studying HF pathogenesis.
• To highlight the potential of human cell-based models, particularly human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), in advancing HF research.
• To emphasize the importance of integrating diverse research approaches for improved HF understanding and treatment development.

Main Methods:

• Exploration of conventional animal experimentation models for HF.
• Focus on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) for studying human-specific genetic and molecular mechanisms.
• Discussion of engineered heart tissues (EHTs) utilizing hiPSC-CMs and scaffold-based approaches for improved physiological relevance.

Main Results:

• hiPSC-CMs provide a platform to study human cardiomyocyte dysfunction and enable personalized research.
• Engineered heart tissues offer a more physiologically relevant 3D environment for studying HF, incorporating cellular, structural, and electrical cues.
• A collaborative approach integrating animal, hiPSC-CM, and clinical data is crucial for dissecting HF mechanisms.

Conclusions:

• Innovative human cell-based models like hiPSC-CMs and EHTs are vital for overcoming the limitations of traditional animal models in HF research.
• These advanced models facilitate a deeper understanding of human-specific HF pathogenesis.
• Integrating insights from diverse models, including rigorous clinical research, is essential for developing more effective HF therapies.